Fineline Cube

Follow:
14435 Articles
Haisco's HSK47388 Receives NMPA Clinical Trial Approval for Autoimmune Diseases
CompanyDrug

Haisco’s HSK47388 Receives NMPA Clinical Trial Approval for Autoimmune Diseases

HutchMed Reports 9% Revenue Dip in H1 2025; FRUZAQLA Sales Grow Despite Overall Decline
Company

HutchMed Reports 9% Revenue Dip in H1 2025; FRUZAQLA Sales Grow Despite Overall Decline

Westgene Partners with BGI Huo-Yan for mRNA Drug Development and Industrialization
CompanyDeals

Westgene Partners with BGI Huo-Yan for mRNA Drug Development and Industrialization

Henlius' HLX43 Approved by FDA for Phase 1 Trial in Thymic Carcinoma Treatment
CompanyDrug

Henlius’ HLX43 Approved by FDA for Phase 1 Trial in Thymic Carcinoma Treatment

Cryofocus Medtech's Cryoadhesion System Gains NMPA Approval for Commercialization
CompanyMedical Device

Cryofocus Medtech’s Cryoadhesion System Gains NMPA Approval for Commercialization

Zai Lab Announces Q2 2025 Results With 10% Revenue Growth Driven by Key Products
Company

Zai Lab Announces Q2 2025 Results With 10% Revenue Growth Driven by Key Products

Sino Biopharmaceutical's LM-24C5 Receives NMPA Approval for Phase 2 Clinical Trials in CEACAM5-Positive Solid Tumors
CompanyDrug

Sino Biopharmaceutical’s LM-24C5 Receives NMPA Approval for Phase 2 Clinical Trials in CEACAM5-Positive Solid Tumors

Eli Lilly Reports Strong Q2 Growth but Shares Dip on Orforglipron Data
CompanyDrug

Eli Lilly Reports Strong Q2 Growth but Shares Dip on Orforglipron Data

Amgen Reports 9% Revenue Growth in Q2 2025 Driven by Key Product Sales
Company

Amgen Reports 9% Revenue Growth in Q2 2025 Driven by Key Product Sales

Sunshine Lake Pharma Makes History With Dual-Entity Restructuring Listing on HKEX
Others

Sunshine Lake Pharma Makes History With Dual-Entity Restructuring Listing on HKEX

NHSA Updates Volume-Based Procurement Policy for Medical Institutions in 11th VBP Tender
CompanyDrug

NHSA Updates Volume-Based Procurement Policy for Medical Institutions in 11th VBP Tender

Neowise Biotechnology's NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy
CompanyDrug

Neowise Biotechnology’s NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy